Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Results For The Quarter Ending 30Th Sep 2020

 The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- 1. UN-AUDITED FINANCIAL RESULT Approval of un-audited financial results of the Company for the quarter and half year ending 30th Sep 2020. Please find attached Limited Review Report with modified opinion from the statutory auditor of the Company M/s. R. Sathyanarayanan & Co and reply to the modified opinion is attached herewith:
12-11-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Quarterly Results And Other Business With The Permission Of The Chair.

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2020 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 12th November 2020 online through video conferencing, to inter alia consider and adopt un-audited financial results for the quarter and six months ended 30th Sep 2020 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public.
02-11-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Sub: Certificate From Practicing Company Secretary For The Half Year Ended 30Th September 2020 Ref: Regulation 40(9) Of The SEBI (LODR) Regulations, 2015

 Please find attached Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the half year ended 30th September 2020. Request you to take the same on record.
23-10-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended September 30, 2020

 Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here
20-10-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended September 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer
19-10-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Sub: Compliance Certificate For The Half Year Ended 30Th September 2020

 Compliance Certificate certifying maintenance of physical and electronic transfer facility under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half year ended 30th September, 2020 is hereby enclosed for your reference.
13-10-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Clarification

 With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Bafna Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed.
23-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Clarification sought from Bafna Pharmaceuticals Ltd

 The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on September 23, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
23-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended September 10, 2020

 Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 10, 2020. For more details, kindly Click here
17-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement Under Regulation 30

 CORRIGENDUM Dear Sir, Sub.:- Outcome of the Board meeting held on 10th Sep 2020 Ref.:- Regulation 30 read with Reg. 33 of SEBI (Lgations and Disclosure Requirements) Regulations 2015 This is further to our letter dated 10th September 2020 regarding outcome of the Board meeting held on 10th September 2020 we would like to bring the following for your kind notice. The Board had approved appointment of : 1. Mr. Battu Harish Laxmaiah (DIN: 06390117) as an Additional Director (Non-executive Director) 2. Mrs. Akilapriya Chandrashekar Raju (DIN: 07590312) as an Additional Director (Non-executive Director ) However inadvertently it was mentioned in the Outcome of the Board meeting : 1. Appointment of Mr. Battu Harish Laxmaiah (DIN: 06390117) as an Additional Director (Non-executive Director- Independent) 2. Appointment of Mrs. Akilapriya Chandrashekar Raju (DIN: 07590312) as an Additional Director (Non-executive Director - Independent)
12-09-2020
Next Page
Close

Let's Open Free Demat Account